Highbridge Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Highbridge Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-50,000	Closed	-$2.3M	–	1700
2017 Q2	$2.3M	Buy	+50,000	New	+$2.43M	0.03%	413
2017 Q1	–	Sell	-49,146	Closed	-$1.9M	–	1606
2016 Q4	$1.9M	Buy	49,146 +44,660	+996%	+$2.02M	0.03%	391
2016 Q3	$227K	Sell	4,486 -4,276	-49%	-$213K	﹤0.01%	1134
2016 Q2	$399K	Buy	+8,762	New	+$403K	0.01%	943
2016 Q1	–	Sell	-121,836	Closed	-$6.89M	–	1704
2015 Q4	$6.89M	Buy	+121,836	New	+$6.19M	0.11%	226
2015 Q3	–	Sell	-219,127	Closed	-$10.5M	–	1744
2015 Q2	$10.5M	Buy	+219,127	New	+$9.29M	0.13%	179
2015 Q1	–	Sell	-12,016	Closed	-$430K	–	1525
2014 Q4	$268K	Buy	+12,016	New	+$228K	﹤0.01%	992
2014 Q1	–	Sell	-43,452	Closed	-$406K	–	1188
2013 Q4	$406K	Buy	+43,452	New	+$424K	﹤0.01%	733

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's NBIX Position: Q3 2017 in Review

Highbridge Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 50,000 shares — an estimated $2.3M sold.

Highbridge Capital Management first reported a position in NBIX in Q4 2013 and held it in 8 quarters. The position peaked at $10.5M in Q2 2015. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

Highbridge Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
Highbridge Capital Management sold 50,000 Neurocrine Biosciences shares in Q3 2017, an estimated $2.3M.
Highbridge Capital Management first reported a position in Neurocrine Biosciences in Q4 2013 and held it in 8 quarters.
Highbridge Capital Management's Neurocrine Biosciences position peaked at $10.5M in Q2 2015.
223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.